文献速递白血病造血干细胞移植与细胞治疗

Ph+急性淋巴细胞白血病异基因移植联合移植后环磷酰胺

Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.
PubMed 文献 · Blood Adv · 2020-01-01

该研究回顾性分析约翰霍普金斯2008至2018年接受移植后环磷酰胺预防GVHD的成人新发Ph+ ALL异基因移植病例,85%在CR1期移植,58%为单倍体移植。CR1患者5年无复发生存率为66%,非清髓预处理、移植时流式MRD阴性及诊断时使用达沙替尼与更好生存相关,供者类型和年龄≥60岁不影响RFS。

要点

  • Ph+ ALL在CR1期接受PTCy单倍体移植可获得66%的5年RFS。
  • 非清髓预处理、移植时MRD阴性和诊断时用达沙替尼与更优OS和RFS相关。
  • 供者类型和受者年龄≥60岁不影响RFS。

核心结论

  • 对初始达沙替尼治疗后达MRD阴性CR1的Ph+ ALL患者,采用非清髓预处理联合PTCy的异基因移植可获得有利结局。

研究设计与样本

  • 回顾性查询约翰霍普金斯骨髓移植数据库,纳入2008至2018年接受alloBMT且以PTCy作为GVHD预防组成部分的成人新发Ph+ ALL患者。

主要发现

  • 69例(85%)移植在CR1期进行,12例(15%)在CR2+期进行;58%为HLA单倍体移植,91.4%患者移植后启动TKI。
  • CR1患者5年RFS为66%。
  • 非清髓预处理、移植时流式MRD阴性及诊断时使用达沙替尼而非伊马替尼与改善OS和RFS相关。
  • 供者类型和受者年龄≥60岁均不影响RFS。
  • 分析全部移植时,CR1期移植(对比CR2+)和移植前MRD阴性与改善RFS相关;多数复发伴随激酶域突变出现。

关键数值与推荐

  • 1年3至4级急性GVHD累积发生率为9%,2年中重度慢性GVHD累积发生率为8%。

临床怎么用

  • Ph+ ALL成人CR1期可考虑非清髓预处理联合PTCy的异基因移植,尤其移植前达MRD阴性者。
  • 移植后应启动TKI,诊断时优先选用达沙替尼可能改善生存。
  • 供者选择可不限于HLA全合,单倍体供者不影响RFS;年龄≥60岁亦非禁忌。

局限性

  • 回顾性单中心数据库分析,样本量有限,结论需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic blood or marrow transplantation (alloBMT) is standard of care for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in first complete remission (CR1). The routine pretransplant and posttransplant use of tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes, but the optimal conditioning regimen, donor type, and TKI remain undefined. The bone marrow transplant database at Johns Hopkins was queried for adult patients with de novo Ph+ ALL who received alloBMT using posttransplantation cyclophosphamide (PTCy) as a component of graft-versus-host disease (GVHD) prophylaxis from 2008 to 2018. Among transplants for Ph+ ALL, 69 (85%) were performed in CR1, and 12 (15%) were performed in second or greater remission (CR2+). The majority of transplants (58%) were HLA haploidentical. Nearly all patients (91.4%) initiated TKI posttransplant. For patients in CR1, the 5-year relapse-free survival (RFS) was 66%. The use of nonmyeloablative conditioning, absence of measurable residual disease (MRD) according to flow cytometry at transplant, and the use of dasatinib vs imatinib at diagnosis were associated with improved overall survival (OS) and RFS. Neither donor type nor recipient age ≥60 years affected RFS. When analyzing all transplants, alloBMT in CR1 (vs CR2+) and the absence of pretransplant MRD were associated with improved RFS. Most relapses were associated with the emergence of kinase domain mutations. The cumulative incidence of grade 3 to 4 acute GVHD at 1 year was 9%, and moderate to severe chronic GVHD at 2 years was 8%. Nonmyeloablative alloBMT with PTCy for Ph+ ALL in an MRD-negative CR1 after initial treatment with dasatinib yields favorable outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Webster JA, Luznik L, Tsai HL, et al. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Adv. 2020. PMID: 33080006. doi:10.1182/bloodadvances.2020002945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。